GYRE THERAPEUTICS, INC.
GYRE · Pharmaceutical Preparations
Latest available SEC filing: 10-Q ·
Latest disclosures
-
Latest financial period: Q3 2026
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
-
Form 10-Q
SEC filing · Filed
-
Weston Claire: Form 4
Insider disclosure · Filed · Report period 03 Aug 2026
-
Form 3
SEC filing · Filed
-
Form 3
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- GYRE · 403783103 - Common Stock, par value $0.001 per share
Company details and SEC sources
CIK 0001124105 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- GYRE on Nasdaq
- SEC industry group
- Pharmaceutical Preparations (Office of Life Sciences)
- Business address
- 12730 High Bluff Drive, Suite 250, San Diego, CA, 92130
- Incorporated in
- DE
- Fiscal year end
- 31 December
- Former names on EDGAR
- CATALYST BIOSCIENCES, INC. (to 27 Oct 2023), TARGACEPT INC (to 19 Aug 2015)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields